COMMUNIQUÉS West-GlobeNewswire

Sequana Medical announces the Annual and Extraordinary General Meetings of Shareholders on 23 May 2024

23/04/2024 - 08:00

PRESS RELEASE REGULATED INFORMATION 23 April 2024, 07:00 am CET Sequana Medical announces the Annual and Extraordinary General Meetings of Shareholders on 23 May 2024 Publication of Annual Report 2023 Ghent, Belgium – [...]

Sequana Medical announces Annual General Meeting of Shareholders on 25 May 2023

23/04/2024 - 07:00

PRESS RELEASE REGULATED INFORMATION 23 April 2024, 07:00 am CET Publication of Annual Report 2023 Ghent, Belgium – 23 April 2024 – Sequana Medical NV (Euronext Brussels: SEQUA) (the " Company " or " Sequana Medical "), [...]

Novartis delivers double-digit sales growth and core margin expansion in Q1; FY 2024 guidance raised

23/04/2024 - 07:00

Ad hoc announcement pursuant to Art. 53 LR Q1 net sales grew +11% (cc 1 , +10% USD) with core operating income up +22% (cc, +16% USD) Key growth drivers continued strong sales momentum including Entresto (+36% cc), [...]

Novartis, au premier trimestre: croissance à deux chiffres du chiffre d’affaires et expansion de la marge core; hausse des prévisions pour 2024

23/04/2024 - 07:00

Annonce événementielle au sens de l’art. 53 RC Résultats du premier trimestre (T1) Chiffre d’affaires net en hausse de +11% (tcc 1 , +10% USD) et du résultat opérationnel core, de +22% (tcc, +16% USD) Les moteurs clés [...]

Idorsia publishes an invitation to a bondholder meeting

23/04/2024 - 07:00

Ad hoc announcement pursuant to Art. 53 LR A bondholder meeting will take place on May 6, 2024, to vote on proposals to amend the terms of the outstanding convertible bonds maturing on July 17, 2024, including an [...]

Press Release: Rilzabrutinib LUNA 3 phase 3 study met primary endpoint in immune thrombocytopenia

23/04/2024 - 07:00

Rilzabrutinib LUNA 3 phase 3 study met primary endpoint in immune thrombocytopenia Pivotal data from the first phase 3 study of a BTKi in immune thrombocytopenia (ITP) underscore the potential of rilzabrutinib to [...]

Communiqué de presse : L’étude de phase III LUNA 3 du rilzabrutinib pour le traitement de la thrombocytopénie immune a atteint son critère d’évaluation primaire

23/04/2024 - 07:00

L’étude de phase III LUNA 3 du rilzabrutinib pour le traitement de la thrombocytopénie immune a atteint son critère d’évaluation primaire Des données pivots de la première étude de phase III d’un BTKi dans la [...]

Curium Enrolls First Prostate Cancer Patients in its Phase 3 SOLAR Trials

23/04/2024 - 06:01

ST. LOUIS, April 23, 2024 (GLOBE NEWSWIRE) -- Curium, a world leader in nuclear medicine, announced today that it has successfully enrolled and scanned patients in its SOLAR clinical trials: The first trial is SOLAR- [...]

Regeneron to Highlight Advances in Genetic Medicine Research at American Society of Gene and Cell Therapy (ASGCT)

22/04/2024 - 23:54

Oral presentations include updated results from clinical study of otoferlin gene therapy DB-OTO demonstrating restoration in children with profound genetic hearing loss Additional presentations cover progress in novel [...]

Generation Bio Announces the Acceptance of Five Abstracts and an Invited Oral Presentation at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting

22/04/2024 - 23:31

CAMBRIDGE, Mass., April 22, 2024 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO) a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, today announced that six [...]

Cidara Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results

22/04/2024 - 23:10

SAN DIEGO, April 22, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX) (the Company), a biotechnology company using its proprietary Cloudbreak ® platform to develop drug-Fc conjugate (DFC) [...]

Arbor Biotechnologies to Present Data Supporting Therapeutic Programs in PH1 and ALS, and the Discovery of a Novel Type V Nuclease at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting

22/04/2024 - 23:09

- Oral and poster presentations showcase data demonstrating pipeline progress and continued advancement of Arbor’s pipeline programs toward the clinic - Oral presentation with data validating aspects of Arbor’s approach [...]

Cidara Therapeutics Announces Receipt of Nasdaq Delinquency Notice

22/04/2024 - 23:06

SAN DIEGO, April 22, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX) (the Company), a biotechnology company using its proprietary Cloudbreak ® platform to develop drug-Fc conjugate (DFC) [...]

TScan Therapeutics Announces Upcoming Presentations at the American Society of Gene and Cell Therapy 27th Annual Meeting

22/04/2024 - 23:01

WALTHAM, Mass., April 22, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR [...]

Scorpius Holdings Announces Receipt of Filing Delinquency Notification

22/04/2024 - 23:00

Reaffirms commitment to regaining compliance with the NYSE American continued listing standards DURHAM, N.C., April 22, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc (NYSE American: SCPX) , an integrated contract [...]

Theriva™ Biologics to Present Preclinical Data Supporting the Potential Synergy of VCN-01 and First-Line Pancreatic Cancer Chemotherapy Regimens at the American Society for Cell and Gene Therapy 27th Annual Meeting

22/04/2024 - 22:35

– Lead product candidate, VCN-01 in combination with liposomal irinotecan demonstrated enhanced anti-tumor effects in a human pancreatic mouse xenograft – – The observed synergy emphasizes VCN-01’s potential in diverse [...]

Ring Therapeutics Announces Presentations at the 27th Annual American Society of Gene and Cell Therapy

22/04/2024 - 22:32

Development of a new class of viral vectors – Anellovectors – with potential to deliver DNA payloads across broad tissue types in redosable manner Anellovectors demonstrate expanded payload capacity and expression of [...]

Excision BioTherapeutics to Present Positive Data from its HSV-1 Keratitis Program, EBT-104, at the ASGCT 2024 Annual Meeting

22/04/2024 - 22:31

Oral presentation to discuss CRISPR-associated gene editing inactivating herpes virus Two poster presentations highlight the potential of EBT-104 for the treatment of HSV-1 Keratitis, demonstrating near-complete virus [...]

Editas Medicine to Present Pre-clinical Data Demonstrating Progression of in vivo Medicines Pipeline at the American Society of Gene and Cell Therapy Annual Meeting

22/04/2024 - 22:31

CAMBRIDGE, Mass., April 22, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage gene editing company, today announced that three abstracts have been accepted for presentation, including one [...]